- Academic Editor
Background: To investigate the incidence of contrast-induced acute
kidney injury (CI-AKI) in patients with acute myocardial infarction (AMI)
undergoing primary percutaneous coronary intervention (PCI) in relation to the
neutrophil to high-density lipoprotein cholesterol ratio (NHR), and to further
compare the predictive value of NHR and the neutrophil to lymphocyte ratio (NLR)
for CI-AKI. Methods: We retrospectively analyzed 1243 AMI patients
undergoing PCI from January 2019 to December 2021, and collected creatinine
within 72 h after PCI. All patients were divided into a CI-AKI group and
non-CI-AKI group according to the definition of CI-AKI, and the clinical
information of the two groups was compared. Potential risk factors for CI-AKI in
AMI patients undergoing primary PCI were screened by using logistic regression
analysis, and receiver operating characteristic (ROC) curves were used to compare
the predictive value of NHR and NLR. Results: A high NHR and high NLR
were correlated with a high incidence of CI-AKI in AMI patients undergoing
primary PCI, and NHR (odds ratio (OR): 1.313, 95% confidence interval (CI):
1.199–1.438) and NLR (OR: 1.105, 95% CI: 1.041–1.174) were independent risk
factors for CI-AKI (p
Cardiovascular interventions have become an important method for the clinical diagnosis and treatment of cardiovascular diseases, and the number of adverse effects caused by contrast agents has also increased. Contrast-induced acute kidney injury (CI-AKI) is the third leading cause of hospital-acquired renal failure, after renal artery hypoperfusion and nephrotoxicity of drugs [1]. The mechanism of CI-AKI is complex and unclear. Its incidence may be related to underlying renal disease, renal artery hypoperfusion, and the toxic effects of contrast agents on renal tubules, which lead to tubular obstruction, renal medullary hypoxia, oxygen-free radical damage, apoptosis, and immune and inflammatory responses [2]. CI-AKI is associated with longer hospital stays and higher health care costs, and has become an important disease affecting the health of the population. However, no effective treatment is available, so the early identification of CI-AKI is critical.
Neutrophils are the predominant leukocyte type in acute inflammation and are mediators of the early inflammatory response. Neutrophils not only release cytotoxic substances but also promote the release of reactive oxygen species, leading to local ischemia, plaque instability, and thrombosis [3]. Several studies have confirmed the inflammatory response as a risk factor for CI-AKI [4, 5]. High-density lipoprotein (HDL) has a strong anti-atherosclerotic function. In healthy populations, HDL also has anti-inflammatory and antioxidant abilities, promotes endothelial repair, and acts as a systemic signal. HDL was reported to correlate with CI-AKI [6]. HDL can regulate activated neutrophils. In contrast, the structure and content of HDL can be altered by activated neutrophils [7]. Therefore, we investigated whether the neutrophil to high-density lipoprotein ratio (NHR) is a novel indicator of inflammation and lipid levels, and predicts the development of CI-AKI. In addition, inflammation-based scores have been widely used to predict the incidence of CI-AKI in recent years, and the neutrophil to lymphocyte ratio (NLR) is an independent risk factor for CI-AKI [8].
Therefore, we further compared the predictive value of NLR and NHR for CI-AKI in patients with AMI undergoing primary percutaneous coronary intervention (PCI).
Between January 2019 and December 2021, 1243 patients with AMI who underwent
primary PCI at Xuzhou Medical University Hospital (Jiangsu Province, China) were
retrospectively and consecutively enrolled in present study. The primary outcome
of this study was the incidence of CI-AKI. AMI includes ST-segment elevation
myocardial infarction (STEMI) and non-ST-segment elevation MI (NSTEMI). AMI [9]
was defined as: the presence of (1) typical chest pain and/or ischemic symptoms
at rest lasting
PCI was performed by an interventional cardiologist using a radial or femoral artery approach according to standard clinical practice. All patients were given aspirin (loading dose, 300 mg), clopidogrel (loading dose, 300 mg), or ticagrelor (180 mg) at the time of presentation, followed by aspirin (100 mg/day), clopidogrel (75 mg/day), or ticagrelor (180 mg/day). The contrast agent used was a low-osmolar nonionic contrast agent with an osmotic concentration of 600–800 mOsm/Kg. After the procedure, depending on the patient’s underlying physical condition, the patient was given an appropriate amount of fluid hydration by an interventional cardiologist to facilitate metabolism of the contrast agent in the body.
Blood samples were collected from the anterior elbow vein prior to PCI, and the
blood samples were tested in our central laboratory, analyzed by the biochemistry
laboratory, and reported uniformly. The XE-5000 automatic hematology analyzer
(Sysmex Co., Kobe, Japan) was used for blood cell analysis. The HLC-723G8
analyzer (Tosoh, Tokyo, Japan) was used to detect glycated hemoglobin, and
the detection reagents were from Tosoh (Shanghai, China) Biotechnology. The Cobas
8000 automatic biochemical analyzer (Roche, Mannheim, Germany) was used to detect
the serum levels of cholesterol, triglyceride, prealbumin, albumin, total
bilirubin, direct bilirubin, fasting blood glucose, uric acid, urea, creatinine,
HDL, and LDL (detection reagents were from Shanghai Deacon Company, Shanghai,
China). The eGFR was calculated using a simplified Modification of Diet in Renal
Disease formula: eGFR (mL/min/1.73 m
The Shapiro-Wilk test was used to characterize the distribution of the data. The
mean
A total of 1243 AMI patients underwent primary PCI. The mean age of the patients
was 63
Compared with patients without CI-AKI, patients who developed CI-AKI were older,
predominantly female, and had a lower left ventricular ejection fraction
(p
Projects | CI-AKI (n = 240) | non-CI-AKI (n = 1003) | p | |
Basic information | ||||
Age, years | 65.49 |
62.76 |
0.003 | |
Sex, female, n (%) | 87 (36.3%) | 229 (22.8%) | ||
High blood pressure, n (%) | 117 (48.8%) | 462 (46.1%) | 0.453 | |
Diabetes, n (%) | 71 (29.6%) | 259 (25.8%) | 0.236 | |
Left ventricular ejection fraction (%) | 51.35 |
53.31 |
0.002 | |
Contrast agent |
147 (61.3%) | 645 (64.3%) | 0.194 | |
Laboratory metrics | ||||
White blood cell count ( |
9.83 |
9.42 |
0.064 | |
Lymphocyte count ( |
1.39 |
1.70 |
||
Neutrophil count ( |
8.43 |
6.91 |
||
NLR | 8.25 |
5.77 |
||
CRP (mg/L) | 14.22 |
14.08 |
0.950 | |
Red blood cell count ( |
4.42 |
4.43 |
0.797 | |
Hemoglobin (g/L) | 137.66 |
138.98 |
0.297 | |
Platelet count ( |
202.92 |
209.93 |
0.107 | |
LN NT-proBNP | 7.17 |
6.78 |
||
cTnT (ng/mL) | 2.54 |
2.02 |
0.619 | |
CK-MB (m/L) | 68.66 |
53.84 |
0.016 | |
Fibrinogen (g/L) | 3.12 |
3.03 |
0.355 | |
AT3 (%) | 83.38 |
83.66 |
0.809 | |
Albumin (g/L) | 38.90 |
38.90 |
0.985 | |
TG (mmol/L) | 1.42 |
1.64 |
0.021 | |
TC (mmol/L) | 4.37 |
4.43 |
0.646 | |
LDL (mmol/L) | 2.73 |
2.74 |
0.809 | |
HDL (mmol/L) | 0.86 |
1.00 |
||
NHR | 10.42 |
7.31 |
||
Serum creatinine ( |
68.88 |
67.57 |
0.628 | |
eGFR (mL/min) | 111.33 |
115.08 |
0.109 | |
Fasting blood sugar (mmol/L) | 7.03 |
6.53 |
0.013 | |
Glycation (%) | 6.69 |
6.61 |
0.490 | |
Drug administration | ||||
Aspirin, n (%) | 240 (100%) | 1001 (99.8%) | 0.489 | |
Clopidogrel, n (%) | 240 (100%) | 1003 (100%) | - | |
B-receptor blockers, n (%) | 204 (85.0%) | 836 (83.3%) | 0.534 | |
ACEI/ARB, n (%) | 150 (62.5%) | 581 (57.9%) | 0.177 | |
Statin, n (%) | 236 (98.3%) | 1003 (100%) | 0.846 | |
CCB, n (%) | 19 (7.9%) | 94 (9.4%) | 0.479 | |
Diuretics, n (%) | 140 (58.3%) | 350 (34.9%) | ||
Nitrates, n (%) | 112 (46.7%) | 454 (45.3%) | 0.695 | |
Low molecular heparin, n (%) | 194 (80.8%) | 762 (76.0%) | 0.254 | |
Values are presented as the mean |
Based on the quartiles of NHR and NLR, all patients were divided into four
groups: NHR, NLR
Quartile | 75–50% | 50–25% | ||
---|---|---|---|---|
NLR | 96 (30.9%) | 74 (23.8%) | 43 (13.8%) | 27 (8.7%) |
NHR | 120 (35.7%) | 61 (21.4%) | 39 (12.5%) | 20 (6.5%) |
NLR, neutrophil to lymphocyte ratio; NHR, neutrophil to high density lipoprotein ratio. |
To assess the risk factors for CI-AKI, the influential factors (age, sex, left
ventricular ejection fraction (LVEF), lymphocytes, neutrophils, NLR, Ln
NT-proBNP, CK-MB, TG, HDL, NHR, fasting glucose, and diuretics) associated with
CI-AKI and eGFR were subjected to univariate analysis. The results showed that
age, sex, LVEF, lymphocytes, neutrophils, NLR, Ln NT-proBNP, CK-MB, TG, HDL, NHR,
fasting glucose, and diuretics were all potential independent risk factors for
CI-AKI. To exclude the confounding factors, the indicators (age, sex, LVEF, NLR,
Ln NT-proBNP, CK-MB, TG, NHR, fasting glucose, and diuretics) not included in NLR
and NHR were included in the multivariate analysis. To avoid interaction between
NLR and NHR as both contained neutrophils, multivariate models were established
separately (A and B), and the multivariate models were validated by
Hosmer-Lemeshow goodness of fit (p
Influencing factors | Univariate analysis | Multivariate analysis (Model A) | Multivariate analysis (Model B) | ||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
Age | 1.018 | 1.006–1.030 | 0.003 | 1.020 | 0.991–1.049 | 0.177 | 0.997 | 0.971–1.024 | 0.849 |
Sex | 1.922 | 1.421–2.599 | 4.257 | 2.201–8.231 | 3.686 | 1.972–6.887 | |||
LVEF | 0.968 | 0.948–0.989 | 0.003 | 0.984 | 0.940–1.031 | 0.503 | 0.969 | 0.927–1.012 | 0.157 |
Lymphocyte count | 0.66 | 0.542–0.803 | |||||||
Neutrophil count | 1.132 | 1.083–1.182 | |||||||
NLR | 1.058 | 1.034–1.082 | 1.105 | 1.041–1.174 | 0.001 | ||||
LN NT-proBNP | 1.338 | 1.171–1.529 | 0.889 | 0.646–1.225 | 0.472 | 0.880 | 0.649–1.193 | 0.411 | |
CK-MB | 1.003 | 1.001–1.006 | 0.017 | 1.000 | 0.996–1.004 | 0.936 | 1.001 | 0.997–1.005 | 0.539 |
TG | 0.814 | 0.687–0.965 | 0.018 | 0.808 | 0.577–1.132 | 0.216 | 1.075 | 0.821–1.409 | 0.598 |
HDL | 0.083 | 0.042–0.162 | |||||||
NHR | 1.192 | 1.149–1.236 | 1.313 | 1.199–1.438 | |||||
eGFR | 1.003 | 0.999–1.008 | 0.110 | ||||||
Fasting blood sugar | 1.062 | 1.011–1.115 | 0.016 | 1.000 | 0.899–1.113 | 0.999 | 1.008 | 0.910–1.116 | 0.882 |
Diuretics | 2.612 | 1.959–3.482 | 1.475 | 0.773–2.817 | 0.239 | 1.670 | 0.898–3.105 | 0.105 | |
CI, confidence interval; OR, odds ratio; LVEF, left ventricular ejection
fraction; NLR, neutrophil to lymphocyte ratio; NT-proBNP, N-terminal natriuretic
peptide precursor; CK-MB, Creatine kinase isozyme; TG, total triglycerides; HDL,
high-density lipoprotein; NHR, neutrophil to high density lipoprotein ratio;
eGFR, estimated glomerular filtration rate.
Model A The variables included in multivariate analysis were the presence of age, sex, LVEF, Ln NT-proBNP, CK-MB, TG, NHR, fasting glucose, and diuretics. Model B The variables included in multivariate analysis were the presence of age, sex, LVEF, NLR, Ln NT-proBNP, CK-MB, TG, fasting glucose, and diuretics. |
Multivariate regression analysis showed that sex, NHR, and NLR were independent
influencing factors of CI-AKI in AMI patients undergoing primary PCI. The
receiver operating characteristic curves of NHR and NLR showed that the area
under the curve of NHR was larger than that of NLR (AUC = 0.723, 95% CI:
0.697–0.748 vs. AUC = 0.668, 95% CI: 0.641–0.694), and the difference was
significant (p
ROC curves of patients with CI-AKI by NLR and NHR. NLR, neutrophil to lymphocyte ratio; NHR, neutrophil to high density lipoprotein ratio; ROC, receiver operating characteristic.
AUC | 95% CI | p | Sensitivity | Specificity | Cut-off | Comparison of AUC | ||
p | Z | |||||||
NLR | 0.668 | 0.641–0.694 | 61.67% | 64.91% | 5.65 | 0.003 | 2.931 | |
NHR | 0.723 | 0.697–0.748 | 70.83% | 66.10% | 7.64 | |||
CI, confidence interval; AUC, area under curve; NLR, neutrophil to lymphocyte ratio; NHR, neutrophil to high density lipoprotein ratio; ROC, receiver operating characteristic. |
In the present study, we found that high preoperative NHR was strongly associated with the incidence of CI-AKI in AMI patients undergoing primary PCI and that NHR was an independent predictor of CI-AKI. Compared with NLR, NHR had better predictive value and better sensitivity and specificity. It can be concluded that NHR is a simple and easy inflammatory marker to predict the incidence of CI-AKI in AMI patients undergoing primary PCI.
In our study, we found that a higher proportion of STEMI patients who developed CI-AKI underwent PCI than NSTEMI patients, which might be due to the fact that STEMI is the result of transmural ischemia (that is, ischemia that involves the full thickness of the myocardium), whereas NSTEMI does not spread through all of the myocardial wall. Thus STEMI patients are hemodynamically unstable and more prone to hypotension or even shock, leading to inadequate renal perfusion and the development of CI-AKI [11]. We analyzed the data and found that the incidence of CI-AKI was higher in patients who used diuretics during treatment. The main effects of diuretics are to promote the excretion of sodium, chloride, and water, further reducing the effective blood volume and decreasing renal perfusion, leading to transient renal impairment and increasing the incidence of CI-AKI.
In recent years, a number of studies have reported the use of inflammatory factors for the assessment of prognosis in cardiac diseases, such as the systemic immune inflammation index, system inflammation response index, NLR, and NHR for the prediction of prognosis in transcatheter aortic valve implantation, off-pump coronary artery bypass, and PCI [12, 13]. CI-AKI is associated with increased morbidity and mortality, particularly in high-risk patients who have undergone PCI. The inflammatory response is an important risk factor for CI-AKI, and neutrophils are a systemic inflammatory marker that mediates the early inflammatory response. After the patient is exposed to the contrast agent, the contrast agent directly damages the kidney, followed by the infiltration of inflammatory cells such as macrophages, natural killer cells, lymphocytes, and especially neutrophils into the damaged tissue, leading to further destruction of the kidney [14]. Poppelaars et al. [15] found that C5aR2-deficient mice had reduced neutrophil activity, resulting in nephroprotective effects that led to lower creatinine levels and reduced acute tubular necrosis. Raup-Konsavage et al. [16] confirmed that peptidyl arginine deiminase-4 from neutrophils plays a pivotal role in renal ischemia/reperfusion-induced AKI. Núñez et al. [17] showed that lymphocytes are involved in the growth, development, rupture, and thrombosis of atherosclerotic plaques and that a decrease in lymphocyte count is associated with increased physiological stress, inflammatory response, and apoptosis in the organism. As in previous studies [18, 19], this study confirmed that neutrophils were increased and lymphocytes were decreased in AMI patients undergoing primary PCI who developed CI-AKI, and that neutrophils and lymphocytes are potential risk factors for CI-AKI.
HDL is a typical biomarker that responds to lipid metabolism and has a protective role in atherosclerotic and inflammatory processes. Its role is to transport excess cholesterol from peripheral tissues back to the liver for excretion [20]. In addition, HDL prevents the accumulation of monocytes into the arterial wall by inhibiting the expression of endothelial cell adhesion molecules. More importantly, HDL inhibits the activation, proliferation, and migration of neutrophils [21]. Cai et al. [22] showed that serum amyloid A leads to enhanced renal inflammation and elevated levels of urinary albumin and renal injury molecule-1, and significantly increases renal oxidative damage, which in turn damages the kidney, whereas HDL inhibits serum amyloid A and reduces the risk of renal injury. Park et al. [6] concluded that low HDL levels in people with normal renal function are at higher risk of chronic kidney disease (CKD), and that elevated HDL levels are associated with a reduced risk of CKD progression. It is recommended that more intensive measures to prevent CI-AKI be considered for patients with CKD with low HDL levels who are scheduled for PCI. Smith et al. [23] found that higher HDL before PCI treatment is associated with a lower incidence of CI-AKI, this view was also confirmed in our study.
The NLR is an effective predictor of cardiovascular risk in both primary and secondary prevention settings [24]. NLR as a mediator reflecting inflammation is being studied as a marker of CI-AKI. The NLR has predictive value not only for the incidence of CI-AKI in NSTEMI patients undergoing PCI [8], but also for STEMI patients as well [25]. Butt et al. [26] observed 1577 patients with AMI and concluded that elevated NLR is an independent predictor of CI-AKI in this patient population, which is consistent with the results of this study.
NHR is the ratio of neutrophils to HDL and combines the advantages of neutrophils and HDL. It is a potential novel biomarker for inflammation and lipids. Recent relevant studies have found that NHR can be used to predict retinal artery embolism [27], metabolic syndrome [28], acute ischemic stroke [29] and to assess the inflammatory process in Parkinson’s disease [30]. It is also widely used in cardiovascular diseases. A previous study by Kou et al. [21] showed that NHR was associated with the degree of coronary stenosis and can be used to predict severe coronary artery stenosis. Huang et al. [31] found that NHR may have predictive prognostic value for long-term mortality and recurrent MI by observing 528 elderly AMI patients (65–85 years), and was superior to the monocyte to HDL ratio and the LDL to HDL ratio. Li et al. [32] showed that NHR is a new independent risk factor for all-cause mortality in peritoneal dialysis patients and that NHR is correlated with kidney injury. Our study results show that NHR is an independent predictor of the incidence of CI-AKI in AMI patients undergoing primary PCI, and its predictive value is significantly better than NLR.
The study had some limitations. First, this was a single-center retrospective observational study. Second, it was difficult to fully control for differences in baseline characteristics between groups. Finally, only preoperative NHR levels were recorded in this study, and postoperative NHR levels were not recorded and evaluated. Therefore, both the impact of preoperative high NHR on CI-AKI and whether treatment to reduce NHR will reduce the incidence of CI-AKI still require further evaluation in prospective randomized controlled trials with large samples.
NHR is not only an easily accessible marker but also an independent risk factor for the development of CI-AKI in patients with AMI undergoing primary PCI. Furthermore, NHR had better predictive value in detecting the incidence of CI-AKI compared with NLR. This helps clinicians to anticipate early and take timely preventive measures, thus reducing adverse events, reducing patients’ medical costs and improving their quality of life.
The datasets generated and analyzed during the current study are not publicly available due to patient privacy, but are available from the corresponding author on reasonable request.
ZW, YL and WL contributed in the conception of the work, conducting the study, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. ZW, YL, GS, HQ, YZ, DZ and WL contributed in the conception of the work, drafting and revising the draft. All authors read and approved the final version of the manuscript.
The study protocol was approved by the ethics committee of the Affiliated Hospital of Xuzhou Medical University (Protocol No. XYFY2022-KL122-01). All patients understood the study procedure and voluntarily signed an informed consent form.
Not applicable.
This research received no external funding.
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.